Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert video report on colorectal cancer from ASCO 2020

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Konstantinos Kamposioras comments on practice changing results from colorectal cancer trials.

He first reports the improved PFS, response rate and duration of response demonstrated in the KEYNOTE-177 trial, testing pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer. He points out on the importance of biomarker analysis in this setting to identify patients who might not respond well to immunotherapy. Secondly he talks about the results of the DESTINY-CRC01 study evaluating objective response to trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer patients and emphasises on the observed potentially dose-related toxicity of this drug. Finally he looks at the updated survival results from the BEACON CRC trial evaluating encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer, establishing the doublet, encorafenib plus cetuximab, as the standard of care in this specific population.


  • LBA4: Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study Thierry André
  • 4000: A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. Salvatore Sienna
  • 4001: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). Scott Kopetz

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.